Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May-Jun;69(3):283.
doi: 10.4103/ijd.ijd_1090_23. Epub 2024 Jun 26.

Desmoglein-1 Deficiency Mimicking Omenn Syndrome

Meltem Comert  1 , Tugba Guler  1 , Ayca Ceylan  1 , İlknur Kulhas Celik  1 , Pinar Karabagli  2 , Tulin Cora  3 , Hasibe Artac  1
Affiliations

Desmoglein-1 Deficiency Mimicking Omenn Syndrome

Meltem Comert et al. Indian J Dermatol. 2024 May-Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
The physical appearance of the patient in the neonatal period (a) and at the age of 20 months, after retinoic aside treatment (b). Photomicrograph showing psoriasiform dermatitis with parakeratosis, hypogranulosus, and spongiosis (hematoxylin and eosin × 200) (c). The palmoplantar keratoderma on the hands of her father (d). The palmoplantar keratoderma on the hands of her mother (e)
See this image and copyright information in PMC

References

    1. Taiber S, Samuelov L, Mohamad J, Barak EC, Sarig O, Shalev SA, et al. SAM syndrome is characterized by extensive phenotypic heterogeneity. Exp Dermatol. 2018;27:787–90. - PubMed
    1. Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014;133:1092–8. - PMC - PubMed
    1. Hammers CM, Stanley JR. Desmoglein-1, differentiation, and disease. J Clin Invest. 2013;123:1419–22. - PMC - PubMed
    1. Frommherz LH, Schempp CM, Has C. Secukinumab for the treatment of SAM syndrome associated with desmoglein-1 deficiency. Br J Dermatol. 2021;184:770–2. - PubMed
    1. Cohen-Barak E, Godsel LM, Koetsier JL, Hegazy M, Kushnir-Grinbaum D, Hammad H, et al. The role of desmoglein 1 in gap junction turnover revealed through the study of SAM syndrome. J Invest Dermatol. 2020;140:556–67. - PMC - PubMed

LinkOut - more resources